1. Home
  2. MGNX vs KVHI Comparison

MGNX vs KVHI Comparison

Compare MGNX & KVHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MGNX
  • KVHI
  • Stock Information
  • Founded
  • MGNX 2000
  • KVHI 1978
  • Country
  • MGNX United States
  • KVHI United States
  • Employees
  • MGNX N/A
  • KVHI 260
  • Industry
  • MGNX Biotechnology: Pharmaceutical Preparations
  • KVHI Radio And Television Broadcasting And Communications Equipment
  • Sector
  • MGNX Health Care
  • KVHI Technology
  • Exchange
  • MGNX Nasdaq
  • KVHI Nasdaq
  • Market Cap
  • MGNX 99.7M
  • KVHI 110.2M
  • IPO Year
  • MGNX 2013
  • KVHI 1996
  • Fundamental
  • Price
  • MGNX $1.82
  • KVHI $5.60
  • Analyst Decision
  • MGNX Hold
  • KVHI
  • Analyst Count
  • MGNX 6
  • KVHI 0
  • Target Price
  • MGNX $3.20
  • KVHI N/A
  • AVG Volume (30 Days)
  • MGNX 630.9K
  • KVHI 30.5K
  • Earning Date
  • MGNX 11-04-2025
  • KVHI 11-06-2025
  • Dividend Yield
  • MGNX N/A
  • KVHI N/A
  • EPS Growth
  • MGNX N/A
  • KVHI N/A
  • EPS
  • MGNX N/A
  • KVHI N/A
  • Revenue
  • MGNX $165,495,000.00
  • KVHI $107,925,000.00
  • Revenue This Year
  • MGNX N/A
  • KVHI N/A
  • Revenue Next Year
  • MGNX N/A
  • KVHI $14.15
  • P/E Ratio
  • MGNX N/A
  • KVHI N/A
  • Revenue Growth
  • MGNX 303.47
  • KVHI N/A
  • 52 Week Low
  • MGNX $0.99
  • KVHI $4.35
  • 52 Week High
  • MGNX $5.10
  • KVHI $6.41
  • Technical
  • Relative Strength Index (RSI)
  • MGNX 51.87
  • KVHI 41.82
  • Support Level
  • MGNX $1.69
  • KVHI $5.38
  • Resistance Level
  • MGNX $1.83
  • KVHI $5.91
  • Average True Range (ATR)
  • MGNX 0.10
  • KVHI 0.25
  • MACD
  • MGNX 0.00
  • KVHI -0.06
  • Stochastic Oscillator
  • MGNX 56.00
  • KVHI 15.36

About MGNX MacroGenics Inc.

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

About KVHI KVH Industries Inc.

KVH Industries Inc provides integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. It offers high-speed Internet and Voice over Internet Protocol (VoIP) services via satellite and integrated 5G/LTE cellular communications to mobile users at sea and on land. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. It operates in several geographic areas, including internationally. Revenues are generated from international locations, mainly consisting of Singapore, Canada, South America, European Union and other European countries, and other regions.

Share on Social Networks: